We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
-12.36%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$2.07B
AUM Growth
-$441M
Cap. Flow
-$81M
Cap. Flow %
-3.92%
Top 10 Hldgs %
24.52%
Holding
315
New
9
Increased
84
Reduced
155
Closed
50

Sector Composition

Rank Sector Weight
1 Technology 27.57%
2 Healthcare 25.36%
3 Industrials 14.78%
4 Consumer Discretionary 12.93%
5 Communication Services 6.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PTC icon
51
PTC
PTC
$16B
$11.8M 0.57%
111,346
-21,267
-16% -$2.3M
ARLO icon
52
Arlo Technologies
ARLO
$1.65B
$11.3M 0.55%
1,800,211
+1,267,979
+238% +$9.27M
CNTY icon
53
Century Casinos
CNTY
$34M
$10.8M 0.52%
1,503,473
+7,168
+0.5% +$66.9K
PRGS icon
54
Progress Software
PRGS
$1.76B
$10.8M 0.52%
237,330
+22,455
+10% +$1.07M
WIX icon
55
WIX.com
WIX
$2.52B
$10.6M 0.51%
162,000
+7,473
+5% +$547K
UTMD icon
56
Utah Medical Products
UTMD
$225M
$10.2M 0.49%
118,890
+2,277
+2% +$194K
FOLD
57
DELISTED
Amicus Therapeutics
FOLD
$9.82M 0.47%
914,275
+284,658
+45% +$2.34M
CCSI icon
58
Consensus Cloud Solutions
CCSI
$647M
$9.5M 0.46%
217,495
+49,489
+29% +$2.46M
ALBO
59
DELISTED
Albireo Pharma Inc
ALBO
$9.25M 0.45%
465,804
-9,187
-2% -$242K
ATEN icon
60
A10 Networks
ATEN
$1.95B
$8.83M 0.43%
614,117
-1,725
-0.3% -$25K
ITRN icon
61
Ituran Location and Control
ITRN
$1.05B
$8.57M 0.41%
350,110
+5,907
+2% +$139K
SNBR
62
DELISTED
Sleep Number
SNBR
$8.26M 0.4%
266,790
-6,136
-2% -$260K
EBS icon
63
Emergent Biosolutions
EBS
$248M
$8.12M 0.39%
261,533
-41,188
-14% -$1.41M
KNSA icon
64
Kiniksa Pharmaceuticals
KNSA
$5.93B
$7.89M 0.38%
814,673
+2,751
+0.3% +$25.7K
ACAD icon
65
Acadia Pharmaceuticals
ACAD
$5.03B
$7.66M 0.37%
543,528
+80,224
+17% +$1.5M
CSW
66
CSW Industrials
CSW
$5.71B
$7.45M 0.36%
72,321
+1,967
+3% +$210K
GBT
67
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.39M 0.36%
231,435
-152,317
-40% -$4.46M
ACLS icon
68
Axcelis
ACLS
$4.33B
$7.17M 0.35%
130,677
-835
-0.6% -$48.4K
TFX icon
69
Teleflex
TFX
$5.98B
$7.02M 0.34%
28,572
-5,478
-16% -$1.6M
GXO icon
70
GXO Logistics
GXO
$5.55B
$6.96M 0.34%
160,912
-8,552
-5% -$473K
FATE icon
71
Fate Therapeutics
FATE
$326M
$6.77M 0.33%
273,033
+27,117
+11% +$748K
MSM icon
72
MSC Industrial Direct
MSM
$6.86B
$6.43M 0.31%
85,667
-4,682
-5% -$384K
AAP icon
73
Advance Auto Parts
AAP
$3.49B
$6.4M 0.31%
36,986
-7,059
-16% -$1.4M
INSM icon
74
Insmed
INSM
$28.6B
$6.15M 0.3%
312,084
+35,935
+13% +$753K
KPTI icon
75
Karyopharm Therapeutics
KPTI
$48M
$5.93M 0.29%
87,722
-1,940
-2% -$178K

Similar funds

Rice Hall James & Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Rice Hall James & Associates held 315 positions worth $2.07B, down 18% from $2.51B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rice Hall James & Associates withdrew a net $81M in Q2 2022, closing 50 positions and reducing 155 holdings. Its most notable exit was Mimecast Limited, an estimated $19.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in Albany International worth $4.99M.

  • Rice Hall James & Associates's largest Q2 2022 buy was Albany International: 63,306 shares worth $4.99M.
  • Rice Hall James & Associates added most to Digital Turbine in Q2 2022, an estimated $30.2M increase.
  • Rice Hall James & Associates's biggest Q2 2022 reduction was Silicon Motion, cutting an estimated $26.3M.
  • Rice Hall James & Associates fully exited Mimecast Limited in Q2 2022, selling an estimated $19.2M.
  • Rice Hall James & Associates's ten largest holdings make up 25% of its $2.07B portfolio in Q2 2022.
  • Rice Hall James & Associates opened 9 new positions and closed 50 in Q2 2022.
  • Rice Hall James & Associates's portfolio value fell 18% quarter-over-quarter to $2.07B.

Based on Rice Hall James & Associates's 13F filing for Q2 2022, filed 8 Aug 2022.